LT2970467T - Antikūnai prieš cd52 - Google Patents
Antikūnai prieš cd52Info
- Publication number
- LT2970467T LT2970467T LTEP14714135.2T LT14714135T LT2970467T LT 2970467 T LT2970467 T LT 2970467T LT 14714135 T LT14714135 T LT 14714135T LT 2970467 T LT2970467 T LT 2970467T
- Authority
- LT
- Lithuania
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794576P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/026159 WO2014151644A2 (en) | 2013-03-15 | 2014-03-13 | Anti-cd52 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2970467T true LT2970467T (lt) | 2019-02-11 |
Family
ID=50391542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14714135.2T LT2970467T (lt) | 2013-03-15 | 2014-03-13 | Antikūnai prieš cd52 |
Country Status (35)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2998405B1 (en) | 2009-05-13 | 2019-12-11 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
| CA2761885A1 (en) | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treating lupus |
| CN110351062B (zh) * | 2014-01-28 | 2022-03-01 | 华为技术有限公司 | 数据传输的指示方法、接入点和终端 |
| US20200299399A1 (en) * | 2017-04-21 | 2020-09-24 | Genzyme Corporation | Treatment of Multiple Sclerosis with Anti-CD52 Antibodies |
| EP3752193A4 (en) * | 2018-02-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | METHODS OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES |
| PE20220568A1 (es) | 2019-05-21 | 2022-04-20 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas |
| WO2021022044A1 (en) * | 2019-07-31 | 2021-02-04 | Forty Seven, Inc. | Depletion regimes for engineered t-cell or nk-cell therapy |
| EP4574840A1 (en) * | 2022-08-15 | 2025-06-25 | The University of Tokyo | Method for producing immunoglobulin or multimer immunoglobulin using filamentous fungus |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1987006265A1 (fr) | 1986-04-17 | 1987-10-22 | Kyowa Hakko Kogyo Co., Ltd. | Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質ｄｃ１１３ |
| JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Ｄｃ―８８ａ誘導体 |
| US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| GB9022547D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
| GB9108056D0 (en) | 1991-04-16 | 1991-06-05 | Hale Geoffrey | Synthetic antigen |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| US5269388A (en) | 1991-11-12 | 1993-12-14 | Stress-Tek, Inc. | Weighing bed |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
| CA2165819C (en) | 1994-04-22 | 2005-12-27 | Nobuyoshi Amishiro | Dc-89 derivatives |
| US5550246A (en) | 1994-09-07 | 1996-08-27 | The Scripps Research Institute | Calicheamicin mimics |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6172213B1 (en) | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
| ES2276708T3 (es) | 1999-11-24 | 2007-07-01 | Immunogen, Inc. | Agentes citotoxicos que comprenden taxanos y su uso terapeutico. |
| BRPI0108923B8 (pt) | 2000-03-03 | 2021-05-25 | Cambridge Antibody Tech Limited | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| US20020132983A1 (en) | 2000-11-30 | 2002-09-19 | Junghans Richard P. | Antibodies as chimeric effector cell receptors against tumor antigens |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| JP4063769B2 (ja) | 2001-12-28 | 2008-03-19 | 中外製薬株式会社 | タンパク質安定化方法 |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| WO2004042032A2 (en) | 2002-11-01 | 2004-05-21 | The Ohio State University Research Foundation | Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia |
| CN1225480C (zh) | 2002-12-18 | 2005-11-02 | 马菁 | 抗cd52单克隆抗体、其编码序列及应用 |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| AU2004226492A1 (en) | 2003-03-31 | 2004-10-14 | Kirin Beer Kabushiki Kaisha | Method of inducing differentiation and proliferating regulatory T cell by anti-CD52 antibody and medicinal composition therefor |
| WO2005017149A1 (en) | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| WO2005042581A2 (en) | 2003-11-01 | 2005-05-12 | Biovation Ltd. | Modified anti-cd52 antibody |
| US20060204496A1 (en) | 2003-11-28 | 2006-09-14 | Tetsuo Kojima | Agonist antibody against heteroreceptor |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| JP2009504136A (ja) | 2005-05-24 | 2009-02-05 | アベスタゲン リミテッド | 慢性リンパ性白血病治療のためのｃｄ５２に対するモノクローナル抗体産生のための組み換え法 |
| DK1888113T3 (da) * | 2005-05-27 | 2014-09-01 | Biogen Idec Inc | Tweak-bindende antistoffer |
| WO2007076927A1 (en) | 2005-12-30 | 2007-07-12 | Merck Patent Gmbh | Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130 |
| WO2007121233A1 (en) | 2006-04-12 | 2007-10-25 | Genzyme Corporation | Methods of treating autoimmune diseases |
| US9498528B2 (en) | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
| KR101583587B1 (ko) | 2006-09-13 | 2016-01-08 | 젠자임 코포레이션 | 캠패스-1ｈ에 의한 다발성 경화증 (ｍｓ)의 치료 |
| JP5337055B2 (ja) * | 2007-02-28 | 2013-11-06 | メルク・シャープ・アンド・ドーム・コーポレーション | 免疫性障害の処置のための組合せ治療 |
| US20100178293A1 (en) | 2007-06-22 | 2010-07-15 | Olaf Weber | Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease |
| WO2010132697A2 (en) | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treatment |
| EP2998405B1 (en) * | 2009-05-13 | 2019-12-11 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
| CA2761885A1 (en) | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treating lupus |
| SI2454284T1 (en) * | 2009-07-15 | 2018-07-31 | Aimm Therapeutics B.V. | Compounds that specifically bind to Gram-positive bacteria |
| DK2593594T3 (en) * | 2010-07-16 | 2017-12-11 | Adimab Llc | ANTIBODY LIBRARIES |
-
2014
- 2014-03-10 AR ARP140100806A patent/AR095199A1/es unknown
- 2014-03-13 TR TR2019/00638T patent/TR201900638T4/tr unknown
- 2014-03-13 MA MA38485A patent/MA38485A1/fr unknown
- 2014-03-13 PL PL14714135T patent/PL2970467T3/pl unknown
- 2014-03-13 KR KR1020157029345A patent/KR20150131286A/ko not_active Ceased
- 2014-03-13 US US14/774,911 patent/US9708407B2/en not_active Expired - Fee Related
- 2014-03-13 CN CN201480028098.XA patent/CN105209495B/zh not_active Expired - Fee Related
- 2014-03-13 PE PE2015001992A patent/PE20151757A1/es not_active Application Discontinuation
- 2014-03-13 EA EA201591796A patent/EA031730B1/ru not_active IP Right Cessation
- 2014-03-13 TW TW103108914A patent/TWI644923B/zh not_active IP Right Cessation
- 2014-03-13 HR HRP20190085TT patent/HRP20190085T1/hr unknown
- 2014-03-13 SG SG11201506932SA patent/SG11201506932SA/en unknown
- 2014-03-13 ES ES14714135T patent/ES2710976T3/es active Active
- 2014-03-13 WO PCT/US2014/026159 patent/WO2014151644A2/en not_active Ceased
- 2014-03-13 DK DK14714135.2T patent/DK2970467T3/en active
- 2014-03-13 EP EP14714135.2A patent/EP2970467B1/en active Active
- 2014-03-13 SI SI201431047T patent/SI2970467T1/sl unknown
- 2014-03-13 HU HUE14714135A patent/HUE041796T2/hu unknown
- 2014-03-13 NZ NZ631473A patent/NZ631473A/en not_active IP Right Cessation
- 2014-03-13 BR BR112015022464A patent/BR112015022464A2/pt not_active Application Discontinuation
- 2014-03-13 LT LTEP14714135.2T patent/LT2970467T/lt unknown
- 2014-03-13 AU AU2014233685A patent/AU2014233685B2/en not_active Ceased
- 2014-03-13 MX MX2015012991A patent/MX2015012991A/es unknown
- 2014-03-13 CA CA2906539A patent/CA2906539A1/en not_active Abandoned
- 2014-03-13 JP JP2016502067A patent/JP6482524B2/ja not_active Expired - Fee Related
- 2014-03-13 PT PT14714135T patent/PT2970467T/pt unknown
- 2014-03-14 UY UY0001035440A patent/UY35440A/es not_active Application Discontinuation
-
2015
- 2015-08-31 DO DO2015000211A patent/DOP2015000211A/es unknown
- 2015-09-02 PH PH12015501932A patent/PH12015501932A1/en unknown
- 2015-09-09 GT GT201500267A patent/GT201500267A/es unknown
- 2015-09-09 IL IL241410A patent/IL241410A0/en unknown
- 2015-09-11 TN TN2015000415A patent/TN2015000415A1/en unknown
- 2015-09-14 CL CL2015002705A patent/CL2015002705A1/es unknown
- 2015-10-13 CR CR20150547A patent/CR20150547A/es unknown
-
2017
- 2017-06-16 US US15/625,361 patent/US20170349665A1/en not_active Abandoned
-
2018
- 2018-12-07 JP JP2018229547A patent/JP2019069960A/ja active Pending
-
2019
- 2019-01-17 CY CY20191100066T patent/CY1121795T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201808451B (en) | Anti-fcrh5 antibodies | |
| IL275103A (en) | Antibody Formulations | |
| GB201322583D0 (en) | Antibodies | |
| SG11201509361TA (en) | Novel antibodies | |
| IL244712B (en) | Anti- pdl1 antibody compositions | |
| ZA201601437B (en) | Antibodies | |
| GB201308658D0 (en) | Antibodies | |
| GB201315486D0 (en) | Antibodies | |
| IL241410A0 (en) | Antibodies against cd–52 | |
| GB201300706D0 (en) | Antibody | |
| IL245488A0 (en) | Anti- ccl17 antibodies | |
| GB201312226D0 (en) | Improved antibodies | |
| GB201318283D0 (en) | Antibodies | |
| PH22013000158U1 (en) | An improved chalice | |
| PH22013000157U1 (en) | An improved chalice | |
| PH22013000156U1 (en) | An improved chalice |